Resistell AG has today closed an oversubscribed series A financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test. Antimicrobial resistance (AMR) is one of the biggest global health challenges today. The emergence of multi-drug resistant pathogens has […]
05
Dec
Dec
ARTIDIS AG, a privately held healthtech company, announced today the successful closure of a CHF 8.8 million seed financing in two rounds securing early clinical validation and the next development phase towards market entry in 2021. The funding will be used to advance the company’s healthtech platform into a large multi-centre clinical study together with […]
17
Dec
Dec
Marija Plodinec, CEO of Artidis (Img: Technologiepark Basel) “Artidis is based on the oldest diagnostic test on earth: palpation,” says Marija Plodinec, CEO and co-founder of Artidis AG. “In a nutshell, we palpate tissue on a molecular level,“ she adds with a twinkle. That’s because instead of a physician’s hand, Artidis runs a fine, high-precision […]